Joseph Magoola
ID: UNCST-2025-R017394
|
Evaluation of outcomes of targeted defaulter tracking on uptake of Malaria and Measles Rubella Vaccine in Uganda from September 2025 to May 2026
REFNo: HS8335ES
Purpose
To assess the effectiveness of defaulter tracking support on malaria vaccine coverage and uptake in Busia, Butambala, Iganga, and Luweero districts in Uganda from September 2025 to May 2026.
Specific Objectives:
1. To determine the change in coverage for malaria, oral polio, pentavalent, and measles vaccines before and after the interventions.
2. To determine changes in malaria, polio, pentavalent, and measles vaccine dropout rates before and after the interventions.
3. To determine the effectiveness of the community-led defaulter tracking system in returning identified children to immunization services.
4. To explore the perspectives of HCWs, and VHTs on factors affecting identification, follow-up, and return of children who default from routine immunization services.
5. To assess how defaulter tracking practices impact the health personnel that provide vaccination service delivery.
|
Uganda |
2026-08-24 13:41:51 |
2029-08-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Eugene Ruzagira
ID: UNCST-2023-R008282
|
A phase 1b randomised double-blinded placebo-controlled study of a Bundibugyo virus disease vaccine, ChAdOx1 Ebola BDBV Vaccine (Recombinant), in healthy participants aged 18 – 55 years in Uganda.
REFNo: HS8453ES
To assess the safety and tolerability
profile of a single dose of ChAdOx1
Ebola BDBV Vaccine (Recombinant) in
healthy participants
To assess the immunogenicity of a single
dose of ChAdOx1 Ebola BDBV Vaccine
(Recombinant) in healthy participants
To assess the safety and tolerability profile of a booster dose of ChAdOx1 Ebola BDBV Vaccine (Recombinant) 6
months following prime vaccination in healthy participants
To assess the immunogenicity of
a booster dose of ChAdOx1 Ebola BDBV Vaccine (Recombinant) 6 months
following prime vaccination in healthy participants
To assess the impact of prior rVSV-ZEBOV-GP or rVSV-SEBOV GP vaccination on the immunogenicity of ChAdOx1
Ebola BDBV Vaccine (Recombinant) in healthy adults
|
Uganda |
2026-08-24 13:40:22 |
2029-08-24 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Maria Dieci
ID: UNCST-2024-R015211
|
Evaluating The effectiveness of Reducing Price Barriers to Pediatric Fever Care on Caregiver Decision-making and Illness Outcomes
REFNo: SS5757ES
The primary objective of this study is to determine the effectiveness and cost-effectiveness of pharmacy-based discounts for azithromycin and incentives for facilitated referrals, well-established practices for managing childhood fevers, on caregiver decision-making and management of childhood febrile illness among children under 5 years of age in Uganda. The unit of analysis will be at the patient level for this objective, and the primary outcome will be illness duration.
The secondary objectives of this study are:
To characterize the effect on care-seeking trajectories among caregivers of children under 5 following an index pharmacy visit for febrile illness. The unit of analysis will be at the patient level.
To characterize the effect on provider behavior and counseling in study sites. The unit of analysis will be at the site level.
To quantify out-of-pocket expenditures on diagnostic testing and medications across study arms. The unit of analysis will be at the patient level.
To compare symptom severity and illness progression over the course of a pediatric fever episode between clients that accessed subsidized care compared to the status quo. The unit of analysis will be at the patient level.
To assess potential indirect effects of the azithromycin and referral price reductions on prescribing practices at pharmacies that are not directly enrolled in the trial. The unit of analysis will be at the site level (surrounding pharmacies and clinics).
|
USA |
2026-08-24 13:33:45 |
2029-08-24 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Richard Ezinga
ID: UNCST-2025-R019501
|
Gene Fusion-Associated Splicing Alterations, and Transcript Isoform Diversity in Acute Lymphoblastic Leukemia Patients
REFNo: HS7887ES
I. To map existing evidence on gene fusion-associated alternative splicing events, transcript isoform alterations, and analytical approaches in Acute Lymphoblastic Leukemia.
II. To identify and characterize recurrent gene fusion-associated splicing alterations and transcript isoform diversity in public ALL RNA-Seq datasets and selected eligible ALL sequences from the Uganda Cancer Institute.
III. To determine the predicted functional consequences of recurrent gene fusion-associated transcript isoforms on protein-domain architecture, molecular interaction networks, and oncogenic pathway dysregulation in Acute Lymphoblastic Leukemia Patients.
IV. To develop and validate a Nextflow-based hybrid computational pipeline for cross-platform confirmation of gene fusion-associated splicing and transcript alterations in Acute lymphoblastic leukemia.
|
Uganda |
2026-08-24 13:30:18 |
2029-08-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
NICHOLAS MWEKWASE
ID: UNCST-2026-R023825
|
BARRIERS AND FACILITATORS TO COMPLIANCE WITH BASIC INFECTION PREVENTION AND CONTROL MEASURES AMONG CAREGIVERS OF NEONATES ADMITTED IN NICU AT KAWEMPE NATIONAL REFERRAL HOSPITAL
REFNo: HS8304ES
To explore the barriers to compliance with basic IPC measures among Caregivers of Neonates admitted to the NICU at Kawempe National Referral Hospital.
To explore the facilitators to compliance with basic IPC measures among caregivers of Neonates admitted to the NICU at Kawempe National Referral Hospital.
|
Uganda |
2026-08-19 19:01:52 |
2029-08-19 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|